Exposure and Effect Assessment of Aerosolized Red Tide Toxins (Brevetoxins) and Asthma

Lora E. Fleming,1,2 Judy A. Bean,3 Barbara Kirkpatrick,4 Yung Sung Cheng,5 Richard Pierce,6 Jerome Naar,6 Kate Nierenberg,4 Lorraine C. Backer,7 Adam Wanner,2 Andrew Reich,8 Yue Zhou,9 Sharon Watkins,8 Mike Henry,4 Julia Zaias,2 William M. Abraham,2 Janet Benson,7 Amy Cassidy,3 Julie Hollenbeck,4 Gary Kirkpatrick,4 Tainya Clarke,2 and Daniel G Baden6

1National Science Foundation National Institute of Environmental Health Sciences Oceans and Human Health Center, University of Miami Rosenstiel School of Marine and Atmospheric Sciences, Miami, Florida, USA; 2University of Miami Miller School of Medicine, Miami, Florida, USA; 3Children’s Hospital Medical Center and University of Cincinnati, Cincinnati, Ohio, USA; 4Mote Marine Laboratory, Sarasota, Florida, USA; 5Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA; 6Center for Marine Science Research, University of North Carolina at Wilmington, Wilmington, North Carolina, USA; 7National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, Georgia, USA; 8Florida Department of Health, Tallahassee, Florida, USA

BACKGROUND: In previous studies we demonstrated statistically significant changes in reported symptoms for lifeguards, general beachgoers, and persons with asthma, as well as statistically significant changes in pulmonary function tests (PFTs) in asthmatics, after exposure to brevetoxins in Florida red tide (Karenia brevis bloom) aerosols.

OBJECTIVES: In this study we explored the use of different methods of intensive ambient and personal air monitoring to characterize these exposures to predict self-reported health effects in our asthmatic study population.

METHODS: We evaluated health effects in 87 subjects with asthma before and after 1 hr of exposure to Florida red tide aerosols and assessed for aerosolized brevetoxin exposure using personal and ambient samplers.

RESULTS: After only 1 hr of exposure to Florida red tide aerosols containing brevetoxin concentrations > 57 ng/m³, asthmatics had statistically significant increases in self-reported respiratory symptoms and total symptom scores. However, we did not see the expected corresponding changes in PFT results. Significant increases in self-reported symptoms were also observed for those not using asthma medication and those living ≥ 1 mile from the coast.

CONCLUSIONS: These results provide additional evidence of health effects in asthmatics from ambient exposure to aerosols containing very low concentrations of brevetoxins, possibly at the lower threshold for inducing a biologic response (i.e., toxicity). Consistent with the literature describing self-reported symptoms as an accurate measure of asthma distress, our results suggest that self-reported symptoms are a valuable measure of the extent of health effects from exposure to aerosolized brevetoxins in asthmatic populations.

KEY WORDS: asthma, brevetoxins, harmful algal blooms (HABs), Karenia brevis, red tides, sensitive populations, spirometry. Environ Health Perspect 117:1095–1100 (2009). doi:10.1289/ehp.0900673 available via http://dx.doi.org/ [Online 13 April 2009]

Florida red tides are a manifestation of the larger growing environmental issue of harmful algal blooms (HABs) (Erdner et al. 2008; Van Dolah 2000). HABs are blooms of microalgae in aquatic environments, causing harm to humans and other animals, particularly by the production of potent natural toxins. Florida red tide is caused by the marine dinoflagellate Karenia brevis, which produces the potent neurotoxins brevetoxins. These toxins cause the death of millions of fish annually in the Gulf of Mexico, as well as morbidity and mortality among marine mammals and sea birds. Exposure to seafood contaminated by brevetoxins is associated with neurotoxic shellfish poisoning in humans, whereas the aerosols of the Florida red tide have been reported to cause respiratory irritation in persons recreating and working in coastal communities during active blooms with onshore winds (Backer et al. 2003, 2005; Fleming et al. 2005a, 2005b, 2007; Watkins et al. 2008; Zaias et al., in press).

Our prior research demonstrated that persons with a physician diagnosis of asthma experience a statistically significant change in their respiratory symptoms and pulmonary function after a 1-hr visit to the beach during a documented Florida red tide; these changes are not seen when the same individuals visit the beach for 1 hr during a non-Florida red tide period (Fleming et al. 2007; Milian et al. 2007). As part of our research, at the same time we collected symptom and pulmonary function data before and after the beach exposure for each individual subject, we collected substantial ambient samples including water for K. brevis cell counts and brevetoxin concentrations; ambient aerosol samples for brevetoxin concentrations and aerosol particle size; and individual personal air samples for brevetoxin concentrations (Cheng et al. 2005a, 2005b, 2005c; Naar et al. 2002; Pierce et al. 2003). In the present study we investigated for the first time which of the measures of brevetoxin concentrations in ambient samples were most closely associated with health effects and whether there were dose–response relationships between these ambient measurements and health outcomes.

Methods

An interdisciplinary team of researchers from federal, state, private, and local organizations have been evaluating aerosolized K. brevis red tide brevetoxin exposures and their possible acute and chronic adverse health effects in humans and animals. The study has been approved by the participating institutional review boards. The study location was Siesta Beach (Sarasota, FL), where prolonged Florida red tide lasting months has become almost an annual event. Although the asthmatic cohort has been studied since 2003, the data used in this analysis were from Florida red tide exposure periods in March 2005 and September 2006.

The study participants consisted of an open cohort of asthmatics with the following

Address correspondence to L.E. Fleming, Department of Epidemiology and Public Health, University of Miami School of Medicine, 1801 NW 9th Ave., Highland Professional Building, Suite 200 (R 669), Miami, FL 33136 USA. Telephone: (305) 243-5912. Fax: (305) 421-4833. E-mail: llfleming@med.miami.edu

This study could not have been performed without the help of the following volunteer investigators: E. Mendes, T. Fleming, C. Fleming, J. Clark, R. Sabogal, F. Yip (CDC); R. Clark, S. Ketchen, P. Castellones, G. Kirkpatrick, P. Stack, C. Higham, S. Rosenthal, D. Dalpra, and M. Harrington. We also thank A. Weidner for her help with the ELISA analysis. Ambient monitoring was performed with help from S. Campbell Niven, J. Lambertso, E. Perineau, C. Gold, L. Zimmerman, T. Blum, S. Hamel, B. Turton, S. Osborne, A. Gomez, D. Krakow, J. McDonald, C. Irvin, and L. Zimmerman. We also thank the Mote Marine Laboratory, the Siesta Key Beach administration, the Tropical Beach and Holiday Inn hotels, and all of our volunteer participants and their families in Sarasota, Florida.

This research was supported by grant P01 ES 10594 and a Minority Supplement from the National Institute of Environmental Health Sciences (NIEHS), by the Centers for Disease Control and Prevention, and the Florida Department of Health. Additional support was received from the Florida Department of Environmental Protection, Florida Red Tide Control and Mitigation; the National Science Foundation (NSF 060343268), and the NIEHS Oceans and Human Health Center at the University of Miami Rosenstiel School (NIEHS 1 P50 ES12736).

The authors declare they have no competing financial interests.

Received 9 February 2009; accepted 13 April 2009.
charactersistics: a self-report of physician-diagnosed asthma; ≥ 12 years of age, history of smoking ≤ 10 years; able to walk on the beach continuously for at least 30 min; and at least 6 months residence in the Sarasota area. For our study, participants spent ≥ 1 hr at the beach in areas with ongoing ambient monitoring. During this time, they could return from the beach at any time if they felt symptomatic, and all participants were encouraged to use any personal medications as needed before, during, and after the study period. Participants were asked not to change their daily asthma management regime on the day of the study.

After obtaining informed consent, we collected detailed baseline information for all subjects (including their medical history and possible confounders) in a baseline questionnaire. Each subject participated in at least one evaluation during an active K. brevis bloom (exposure period) and in one evaluation during a period when there was not a bloom (nonexposure period), although only the exposure period data were used for the analysis. Both evaluations included prebeach and postbeach questionnaires, nasal swab sampling, and spirometry. The prebeach and postbeach questionnaires collected information on recent medical history and medication use, as well as symptoms and possible confounders (e.g., smoking).

Each study participant carried an IOM portable, self-contained weather station near a high-volume air particle impactor and the ambient air samplers was used to monitor the air temperature, relative humidity, wind speed, and direction, as described previously (Cheng et al. 2005a, 2005b, 2005c; Naar et al. 2002; Pierce et al. 2003). Water samples were collected twice daily in 1-L glass bottles from the surf zone adjacent to the high-volume air sampler locations. The water samples were analyzed for K. brevis cell counts and for brevetoxin concentrations using both the brevetoxin enzyme-linked immunosorbent assay (ELISA) and liquid chromatography-mass spectroscopy (LC-MS) analysis (Fleming et al. 2007; Naar et al. 2002; Pierce et al. 2003).

Air samples for toxin and particulate size were collected using two types of high-volume samplers (high-volume filter and high-volume air particle impactors equipped to capture aerosol particles by size) and a personal sampler of the subject breathing zone. We measured brevetoxins by the high-volume sampler and the personal sampler. For the high-volume filter samplers, six 4-hr air filter samples and eight 1-hr air filter samples were measured at a sampling flow rate between 1.6 and 2.0 m³/min. The 1-hr personal exposure of each participant was measured using an individual personal air sampler placed near the breathing zone; the sampling flow rate for the personal sampler was 9-L/min (Cheng YS, personal communication). For the personal samples, we used only the brevetoxin ELISA because it had a lower limit of detection (LOD) than LC-MS, which is important given the low flow rate of the personal air sampler and the small size of the filter paper to be analyzed for brevetoxins. The ambient samples could be analyzed by both LC-MS and brevetoxin ELISA because the flow rate of the ambient air sampler was substantially higher and the filter paper was larger.

The brevetoxin ELISA measures any substance (parent toxins and toxins derivatives/metabolites) containing the brevetoxin type 2 backbone structure. As such, the reported concentration represents the total amount of brevetoxin-like compounds present in the sample and may also include toxins and/or derivatives that have not yet been chemically described. The LC-MS levels reported in this study represent only the sum of the concentrations of five specific brevetoxins that could be present in a given sample (PbTx-1, PbTx-2, PbTx-3, PbTx-9, and PbTx-3 42-carboxylic acid). During the 2005 and 2006 exposure periods, the LOD for individual brevetoxins in seawater was 0.03 μg/L using LC-MS and 0.6 ng/sample using the brevetoxin ELISA for all brevetoxins. The LOD for the LC-MS analysis of the ambient air was 0.01 ng/mL for individual brevetoxins; the ELISA LOD for both the ambient and personal samples was 0.6 ng/sample for all brevetoxins combined.

Exposure and health assessment. In previous analyses involving the asthmatic cohort, “exposure” was defined as spending 1 hr on the beach during a study day when a) K. brevis cells above background levels (i.e., > 5,000 cells/L) and brevetoxins were detected by LC-MS and ELISA in the water, and b) brevetoxins were detected in the ambient air monitors by LC-MS and ELISA (Fleming et al. 2005b, 2007; Milian et al. 2007). However, no attempt was made previously to assign individual exposure levels or to use the personal air sampler data. In this analysis, each subject who had participated in a study during an active Florida red tide was assigned a) the ELISA brevetoxin level from their individual personal air sampler (personal ELISA); b) the ELISA brevetoxin level from the hourly ambient air sampler (ambient ELISA) that corresponded to their individual beach walk time; and c) the LC-MS brevetoxin level from the hourly ambient air sampler (ambient LC-MS) that corresponded to their individual beach walk time. The ambient sampler brevetoxin concentrations were calculated from the hourly samples corresponding to the sampling time of each personal sample. When a personal sample was taken during a portion of two hourly ambient samples, the corresponding ambient concentration was calculated by multiplying the hourly sample with the fraction of time the personal sample was taken during each of the particular hourly samples and then summing the two concentrations.

We asked questions about the presence of symptoms consistent with asthma (i.e., eye,

Table 1. Demographics of 87 study participants with physician-diagnosed asthma.

| Variable                              | No. (%)          |
|---------------------------------------|------------------|
| Age (years; mean ± SD (range))        | 44.9 ± 19.2 (12.0–79.0) |
| Female                                | 52 (59.8)        |
| White                                 | 85 (97.7)        |
| Hispanic                              | 1 (1.2)          |
| Years with diagnosis (mean ± SD)      | 16.9 ± 25.2      |
| Currently use asthma medications a    | 68 (88.3)        |
| Positive history of Florida red tide symptoms with exposure | 77 (90.0) |
| Current smoker                        | 8 (12.3)         |
| Hospitalized ≥ 1 time in past year from respiratory causes | 11 (13.1) |
| Used medications a within 12 hr before study exposure | 30 (34.5) |
| Live ≥ 1 mile from coast b            | 55 (63.2)        |

aAsthma medications predominantly beta, agonists. bAt time of ambient LC-MS brevetoxin measurement.
Asthma and brevetoxin exposure

For the symptom data, analyses were performed using the distribution of the exposure measures by quartiles and by above/below the median of the ambient brevetoxin level. For pulmonary function data, we compared the mean differences between the different groups above and below the mean, the median, and by quartiles, depending on the particular data distribution. Statistical hypothesis testing was performed using paired t-test for continuous data and McNemar’s test for categorical data to compare prebeach and postbeach data (Kleinbaum et al. 1982). The McNemar’s test at 0.05 level of significance uses only the data on the diagonal of the two-by-two table, which indicates a change; thus, subjects who came to the beach reporting no symptom and left reporting a particular symptom were compared with subjects who came to the beach reporting a symptom and left reporting no particular symptom. For the symptom score, the prebeach walk value of each individual was compared with that individual’s postbeach walk value using a two-tailed paired t-test at the 0.05 level of significance. In addition, we performed correlation analyses between individual pulmonary function tests (PFTs) and the ambient measures, as well as multivariable regression analysis with differences between pre- and post-PFTs (as the outcome variable), ambient levels, medication use, sex, age, and geographic proximity of residence to the coast.

Results

There were 87 asthmatic persons ≥ 12 years of age who participated in at least one exposed study period during 2005–2006, with a mean age (± SD) of 44.9 ± 19.2 (range, 12.0–79.0) (Table 1). The majority (56%) were white, non-Hispanic females with many years of asthma diagnosis.

Ambient exposure.

Among the 87 people with a personal sample ELISA, the mean (± SD) level was 73.3 ± 78.9 ng/m³, with a range of 0–366.2 ng/m³ and a median of 45.7 ng/m³. For the ambient hourly sample ELISA, the mean level was 161.5 ± 96.3 ng/m³, with a range of 0–375.4 ng/m³ and a median of 141.0 ng/m³. For the ambient hourly sample LC-MS, the mean level was 53.4 ± 32.9 ng/m³, with a range of 0–117.5 ng/m³ and a median of 56.8 ng/m³.

Upon review, the hourly ambient LC-MS measurements had the strongest associations with the health end points (i.e., symptoms and pulmonary functions); therefore, only the associations between the hourly LC-MS ambient measurements of aerosolized brevetoxins and the health end points are summarized below.

Report of symptoms. Symptoms yes/no.

For the individuals having an hourly ambient LC-MS brevetoxin level above the median

---

**Table 2. Summary of ambient data during exposed study periods: K. brevis cell counts, total brevetoxins in water, and from high-volume and personal air samplers.**

| Date       | Temperature (°C) [mean ± SD] | Humidity (%) [mean ± SD] | Wind speed (mph) [mean ± SD] | Wind direction index [mean ± SD] | Range of K. brevis in water (cells/L) | Water: range of total brevetoxins (µg/m³) | High-volume air: total brevetoxins (µg/m³) [mean ± SD] | Personal air: average TWA (µg/m³) [mean ± SD] |
|------------|-----------------------------|--------------------------|-----------------------------|--------------------------------|-------------------------------------|------------------------------------------|---------------------------------------------|---------------------------------------------|
| 2005       |                             |                          |                             |                                |                                      |                                          |                                             |                                             |
| 11 Mar     | 18.8 ± 0.4                  | 72 ± 3                   | 6.1 ± 3.3                   | 0.76 ± 0.18                   | 54,000–200,000                     | 2.25–11.95                              | 39 ± 13.0                                  | 41.4 ± 24.7                                 |
| 12 Mar     | 18.7 ± 0.8                  | 34 ± 7                   | 6.1 ± 1.8                   | 0.50 ± 0.40                   |                                      | 27.8 ± 11.6                              | 77.5 ± 49.2                                | 26.1 ± 19.5                                 |
| 13 Mar     | 20.0 ± 0.4                  | 89 ± 2                   | 9.5 ± 1.4                   | 0.51 ± 0.10                   |                                      | 21.2 ± 6.9                               | 18.5 ± 14                                  |                                             |
| 14 Mar     | 20.6 ± 0.2                  | 95 ± 1                   | 7.6 ± 1.5                   | 0.40 ± 0.09                   |                                      | 22.3 ± 13.3                              |                                             |                                             |
| 2006       |                             |                          |                             |                                |                                      |                                          |                                             |                                             |
| 22 Sep     | 29.5 ± 0.5                  | 72 ± 2                   | 9.3 ± 2.5                   | 0.52 ± 0.35                   | 694,000–4,280,000                   | 16.69–69.26                             | 46.7 ± 13.7                                 | 68.1 ± 64.2                                 |
| 23 Sep     | 33.3 ± 1.4                  | 48 ± 7                   | 5.5 ± 1.4                   | 0.23 ± 0.29                   |                                      | 59.7 ± 31.0                              | 68.2 ± 97.1                                |                                             |
| 24 Sep     | 32.6 ± 1.4                  | 57 ± 6                   | 6.3 ± 1.2                   | 0.84 ± 0.17                   |                                      | 74.7 ± 25.1                              | 158.0 ± 90.4                               |                                             |

TWA, time-weighted average.

LOD of K. brevis = 1,000 cells/L. LOD of PbTx water = 0.03 µg/L. High-volume air sampler measured by LC-MS; LOD = 0.01 ng/m³. Personal air sampler measured by ELISA; LOD = 0.6 ng/sample.
(i.e., 56.8 ng/m³), statistically significant differences for upper and lower respiratory tract symptoms (i.e., cough, wheeze, throat irritation, chest tightness, and nasal irritation) were seen when examining the change from “no symptom” before beach exposure to “yes symptom” after beach exposure (Table 3). For below the median, there was only a significant report of chest tightness.

We also observed statistically significant differences for both above and below the median brevetoxin level for those without medications within 12 hr of going to the beach (no medications). Those who lived ≥ 1 mile from the coast (far) had significant reports for all respiratory symptoms (data not shown). For those who lived close to the coast or reported using medications, only report of cough and chest tightness were significantly increased above the median.

We observed statistically significant differences in the asthmatics in the highest exposure quartile of hourly ambient LC-MS brevetoxin level compared with those in the lowest exposure quartile with respect to the seven respiratory symptoms (Table 3). Overall, those in the highest exposure quartile reported significantly more respiratory symptoms than those in the lowest exposure quartile.

**Symptom scores.** For the hourly ambient LC-MS brevetoxin level, the difference in the mean symptom scores pre- and post-exposure above the median brevetoxin level were statistically significant (Table 4). For below the median, we found no significant differences in the mean pre/postexposure respiratory symptom scores. In addition, the mean differences in the symptom scores were increased for the hourly ambient LC-MS above the median compared with those below the median (mean ± SD: 4.14 ± 3.46 vs. 0.32 ± 3.51, respectively).

We found statistically significant differences above the median brevetoxin level for the mean difference in the pre/postexposure respiratory symptom for those both with and without medications within 12 hr of going to the beach (Table 4). For below the median, there were no significant differences in the mean pre/postexposure respiratory symptom scores. The mean differences in the symptom scores were increased above the median brevetoxin level compared with those below the median (no medications: 3.89 ± 2.97 vs. 1.35 ± 3.86, respectively; with medications: 5.11 ± 5.06 vs. 0.67 ± 3.01, respectively). We also observed statistically significant differences above the median for the mean difference in the pre/postexposure respiratory symptom scores. The mean differences in the symptom scores were increased above the median brevetoxin level compared with those below the median (far: 4.44 ± 3.71 vs. 0.64 ± 3.03, respectively; close: 2.89 ± 2.32 vs. 0.06 ± 4.12, respectively).

**PFTs.** None of the comparisons between the differences in the means above and below the median for the personal ELISA, or the hourly ambient ELISA and LC-MS brevetoxin levels were statistically significant (Table 5; data are shown only for the hourly ambient LC-MS). We found considerable variation in the pulmonary function data, and not all the mean differences were positive (i.e., demonstrating decreased pulmonary function after exposure compared with before). Only the personal ELISA PFT results demonstrated a consistent pattern where the above-the-median pulmonary function differences were greater than the below-the-median pulmonary function differences (data not shown).

The correlations between the pre/post-exposure pulmonary function differences for each individual pulmonary function measures with the personal ELISA and the hourly ambient ELISA and LC-MS brevetoxin levels were negative (i.e., as the measured brevetoxin level increased, the difference in individual pulmonary functions decreased); however, these results were nonsignificant and very small, ranging from $r = -0.04$ to $-0.14$ (data not shown). Finally, using multiple regression with pre/postexposure FEV₁ score as the outcome measure predicted by the model of ambient level, asthma medication use, sex, age, and proximity, we found no significant results. The very small $R²$ (0.008) indicated that < 1% of the variation in mean pre/postexposure FEV₁ score difference could be accounted for by these variables (data not shown).

**Discussion**

In this study we examined the possible dose–response relationship between health effects (i.e., reported symptoms and PFT results) and exposure to brevetoxins measured during 1 hr of exposure to Florida red tide aerosols (i.e., by the personal ELISA and the hourly ambient ELISA and LC-MS). We found strong associations between the two ambient and one personal sampler brevetoxin measures. There was a statistically significant and positive dose–response relationship between reported asthma symptoms with all the ambient measures, particularly with the ambient LC-MS, for brevetoxin aerosols > 57 ng/m³ (the median brevetoxin level as measured by LC-MS from the hourly ambient sampler). We also observed an association between report of asthma symptoms for persons with less-severe asthma (i.e., not on medications) and persons who lived > 1 mile from the coast, but without a dose–response relationship, as measured by the hourly ambient LC-MS. No association was found between pulmonary function changes and the three brevetoxin measures using various methods of data analysis, nor was any dose–response relationship apparent.

The finding of a greater association between report of symptoms and the ambient LC-MS monitoring as opposed to the personal and ambient ELISA monitoring for brevetoxins is not unexpected. The ELISA measures many components of the brevetoxin structure, including a recently discovered compound, brevenal, that has been found to be a natural antagonist

| Symptoms          | Overall (n = 87) | Ambient LC-MS brevetoxin level: median | Ambient LC-MS brevetoxin level: percentile |
|-------------------|-----------------|----------------------------------------|-------------------------------------------|
|                   | Pre/post (n²)   | Pre/post (n²)                           | Pre/post (n²)                             |
|                   | $p$-Value       | $p$-Value                               | $p$-Value                                 |
| Cough             | 41              | 0.0001                                 | 5                                         |
|                   | 0.13            | 0.0001                                 | 0.26                                      |
|                   | 30              | 0.0001                                 | 15                                        |
|                   |                 |                                       | 0.0001                                    |
| Wheezing          | 17              | 0.01                                  | 1                                         |
|                   | 2               | 0.06                                  | 0.56                                      |
|                   | 15              | 0.0001                                 | 6                                         |
|                   |                 |                                       | 0.01                                      |
| Throat irritation | 34              | 0.0001                                 | 4                                         |
|                   | 0.37            | 0.0001                                 | 0.41                                      |
|                   | 22              | 0.0001                                 | 13                                        |
|                   |                 |                                       | 0.0003                                    |
| Shortness of breath | 21            | 0.02                                  | 3                                         |
|                   | 0.56            | 0.0003                                 | 1.00                                      |
|                   | 16              | 0.01                                  | 9                                         |
|                   |                 |                                       | 0.01                                      |
| Chest tightness   | 28              | 0.0001                                 | 6                                         |
|                   | 0.02            | 0.0003                                 | 0.16                                      |
|                   | 11              | 0.0002                                 | 7                                         |
|                   | 0.94            | 0.02                                   | 0.03                                      |
| Nasal irritation  | 29              | 0.02                                  | 8                                         |
|                   | 0.56            | 0.058                                 | 0.32                                      |
|                   | 16              | 0.058                                 | 3                                         |
|                   |                 |                                       | 0.66                                      |
| Eye irritation    | 11              | 0.23                                  | 3                                         |
|                   | 0.71            | 0.058                                 | 3                                         |
|                   | 8               | 0.058                                 | 2                                         |
| Headache         | 16              | 0.10                                  | 1                                         |
|                   | 0.59            | 0.058                                 | 0.56                                      |
|                   | 8               | 0.058                                 | 2                                         |
| Itchy skin       | 7               | 0.37                                  | 1                                         |
|                   | 0.41            | 0.058                                 | 0.56                                      |
|                   | 5               | 0.058                                 | 2                                         |
| Diarrhea          | 0               | 0.66                                  | 0                                         |
|                   | 0               | 0.08                                  | 0                                         |
| Other             | 6               | 0.16                                  | 3                                         |

*Persons who came to the beach with no symptom and left with a symptom. *Evaluated by McNemar’s test.

1098

VOLUME 117 | NUMBER 7 | July 2009 • Environmental Health Perspectives
to brevetoxins (Abraham et al. 2005a, 2005b; Bourdelais et al. 2004; Naar et al. 2002). The LC-MS is specific for individual brevetoxins, particularly brevetoxin 2 and 3 (PbTx-2 and PbTx-3, respectively); these brevetoxins have been associated with the most significant respiratory effects in ashamitic sheep and other animal models (Abraham et al. 2005a, 2005b; Benson et al. 2005). In the future, we plan to measure brevetoxins using both the ELISA and LC-MS for the personal samplers because the personal samplers should more accurately capture the breathing zone of the individual compared with the ambient monitors.

In the present study we were able to detect significant differences and a dose–response relationship for the reported symptoms, but not for the PFTs. As pointed out by Stemple and Fuhlbrügge (2008), a major limitation in the interpretation of all asthma literature is the inconsistency in the definition of response to pulmonary function testing. They concluded that response must be defined as a combination of self-report of symptoms and objective measures (such as PFTs). To address this issue, in future studies we will include more precise measures of asthma severity as part of the pre-exposure health assessment, as well as assessment of exhaled condensates for inflammatory markers. Of note, in prior studies of very healthy lifeguards and general recreational beach goers exposed to Florida red tide aerosols, significant differences were detected only in the reported symptoms, not in the PFTs (Backer et al. 2003, 2005). Based on prior research on the particle size of the Florida red tide aerosol, 75–85% of the aerosol remains in the nasal passages and does not reach the lung (Cheng et al. 2005a, 2005b, 2005c). Furthermore, based on data from the sheep model of asthma and Florida red tide, it appears that the 1-hr exposure on the beach to brevetoxins in aerosols of Florida red tide for the asthmatic study subjects may represent a relatively low exposure level at a value near the toxicity threshold (Abraham W, personal communication).

In the present study, the subjects ideally performed their pulmonary function testing as soon as they returned from their 1 hr of beach exposure, but it is possible that because of inadvertent delays in testing, air conditioning of the study testing vehicle, or use of asthma medication, any true changes in pulmonary function were not detected. Furthermore, it is also possible in some cases that detectable pulmonary function changes were delayed by hours or even days, and were thus not detected by immediate PFTs. Of note, these asthmatic subjects have reported symptoms lasting up to at least 5 days after from their 1 hr study exposure (Kirkpatrick et al. 2009). In addition, Kirkpatrick et al. (2006) reported increases in emergency room admissions for asthma, pneumonia, and bronchitis noted in coastal residents during active Florida red tides. Finally, it is also possible that the sample size of the asthmatic participants was not large enough to address the very large variability in the pulmonary function testing results typically seen in asthmatics.

In a previous study (Fleming et al. 2007) we noted that symptom scores were significantly higher for study participants reporting no use of asthma medications in the 12 hr prior to the study exposure (used as a surrogate measure of less-severe asthma) after the 1 hr of study exposure. This was also observed in the present analysis, but without a dose–response relationship to brevetoxin exposure measurement. Both coastal and inland residents had been shown to report an increased symptom score after 1 hr of study exposure in a previous study based on symptom score (Milian et al. 2007). In that analysis, only inland residents had a significant report of asthmatic symptoms, again without a dose–response relationship to brevetoxin exposure measurement. The lack of dose–response relationship may mean that asthmatics without medications or who have not had recent ambient red tide exposure because of living inland are more sensitive to the effects of brevetoxins than those using medications and living in coastal areas with constant ambient exposure. Data from the sheep model and Florida red tide indicate that the medications commonly used in asthma management mitigate the effects of the toxins (Abraham et al. 2005a, 2005b).

Another possible limitation to the present study is the reliance on self-reported data for the symptoms. However, despite variable reliability (Chen et al. 2006; Martínez-Moragon et al. 2006), self-report of symptoms is one of the cornerstones of asthmatic diagnosis and clinical care (Stemple and Fuhlbrügge 2008). Of note, an important strength of the present study was the comparison of each individual with themselves, decreasing the possible effects of individual confounders (such as smoking, obesity, and work environment). The study participants (and researchers) have no way of knowing the amount (or even presence) of exposure they received at the time of beach exposure or during the postexposure questionnaire administration, as the brevetoxin analytical results are not received for many days after the field study has been completed.

Conclusions

In previous studies, we demonstrated statistically significant changes in reported symptoms for lifeguards, general beach goers, and asthmatics, as well as statistically significant changes in PFTs in asthmatics, after exposure to brevetoxins in Florida red tide aerosols. In the present study we explored the use of intensive ambient and personal air monitoring in the characterization of these exposures and their possible relationship to health effects in the asthmatic study population. We found that hourly ambient air monitoring for brevetoxins as measured by LC-MS was strongly associated with symptom report. Our results suggest that self-reported symptoms are a valuable measure of the extent of health effects from exposure to aerosolized brevetoxins in asthmatic populations. After only 1 hr of exposure to brevetoxins in Florida red tide aerosols, the asthmatics had statistically significant changes in their reported respiratory symptoms and symptom scores for brevetoxin aerosols > 57 ng/m³ (as measured by LC-MS). Significant increases in self-reported symptoms were also observed for those not using medications and those living ≥ 1 mile from the coast. These associations were not seen with the pulmonary function testing. This lack of association between brevetoxin exposure and PFT results may represent

Table 4. Pre/postexposure mean difference in respiratory symptom score above and below the median brevetoxin level measured by the hourly ambient LC-MS (n = 87).

| Below median | Above median |
|--------------|--------------|
| Pre/postexposure mean difference in symptom score (± SD) | Pre/postexposure mean difference in symptom score (± SD) |
| p-Value* | p-Value* |
| All participants | 0.32 ± 3.51 | 0.57↓ | 4.14 ± 3.46 | 0.0001 |
| Used asthma medications within 12 hr before study exposure | 0.67 ± 3.10 | 0.34↑ | 5.11 ± 5.06 | 0.02 |
| No | 1.38 ± 3.68 | 0.11↑ | 3.89 ± 2.97 | 0.0001 |
| Distance of residence from coast | | | | |
| Close (< 1 mile) | 0.06 ± 4.12 | 0.95 | 2.89 ± 2.32 | 0.006 |
| Far (> 1 mile) | 0.64 ± 3.03 | 0.33 | 4.44 ± 3.71 | 0.0001 |

*Evaluated by paired t-test.

Table 5. PFT mean differences pre- and post-exposure above and below the median brevetoxin level as measured by ambient LC-MS (n = 87).

| PFT | Exposure level | Pre/postexposure mean difference (mL) (± SD) | p-Value* |
|-----|----------------|---------------------------------------------|----------|
| FEV1 | Above median | 27.3 ± 123.0 | 0.62 |
| Below median | 39.8 ± 113.8 | | |
| FVC | Above median | 10.0 ± 128.5 | 0.10 |
| Below median | 61.4 ± 159.4 | | |
| FEF 25–75 | Above median | −22.3 ± 333.97 | 0.32 |
| Below median | 40.2 ± 234.9 | | |
| PEF | Above median | 224.3 ± 500.1 | 0.95 |
| Below median | 217.9 ± 560.2 | | |

*Evaluated by t-test of difference in mean differences.
insensitivity or timing issues of the pulmonary function measurements and/or exposure to brevetoxins near the threshold of toxicity, both of which will be explored in the future.

References

Abraham WM, Bourdelais AJ, Ahmed A, Serebriakov I, Baden. 2005a. Effects of inhaled brevetoxins in allergic airways: toxin-allergen interactions and treatment. Environ Health Perspect 112:632–637.

Abraham WM, Bourdelais AJ, Sabater JR, Ahmed A, Lee TA, Serebriakov I, et al. 2005b. Airway responses to aerosolized brevetoxins in an animal model of asthma. Am J Respir Crit Care Med 171:26–34.

Backer LC, Fleming LE, Rowan A, Cheng Y, Benson J, Pierce R, et al. 2003. Recreational exposure to aerosolized brevetoxins during Florida red tide events. Harmful Algae 2:19–28.

Backer LC, Kirkpatrick B, Fleming LE, Cheng Y, Pierce R, Bean J, et al. 2005. Occupational exposure to aerosolized brevetoxins during Florida red tide events: impacts on a healthy worker population. Environ Health Perspect 113:844–849.

Benson JM, Hahn FF, March TH, McDonald JD, Gomez AP, Supor MJ, et al. 2005. Inhalation toxicity of brevetoxin 3 in rats exposed for twenty-two days. Environ Health Perspect 112:626–631.

Bourdelais AJ, Campbell S, Jacocks H, Naar J, Wright JL, Carsi J, et al. 2004. Brevenal is a natural inhibitor of brevetoxin action in sodium channel receptor binding assays. Cell Mol Neurobiol 24(4):553–563.

Chen E, Herman C, Rogers D, Oliver-Wolker T, Strunk RC. 2006. Symptom perception in childhood asthma: the role of anxiety and asthma severity. Health Psychol 25(3):389–395.

Cheng YS, McDonald J, Kracko D, Irvine CM, Zhou Y, Pierce RH, et al. 2005a. Concentrations and particle size of airborne toxic algae (brevetoxin) derived from ocean red tide events. Environ Sci Technol 39:3443–3449.

Cheng YS, Villareal TA, Zhou Y, Gao J, Pierce JH, Wetzel D, et al. 2005b. Characterization of red tide aerosol on the Texas coast. Harmful Algae 4(1):97–95.

Cheng YS, Zhou Y, Irvine CM, Pierce RH, Naar J, Backer LC, et al. 2005c. Characterization of marine aerosol for assessment of human exposure to brevetoxins. Environ Health Perspect 1:638–643.

Erdner DL, Dyble J, Brand LE, Parker MS, Stevens RC, Moore SK, et al. 2008. Centers for Oceans and Human Health: a unified approach to the challenge of harmful algal blooms. Environ Health Perspect 112(suppl 1):133–141.

Fleming LE, Backer LC, Baden DG. 2005a. Overview of aerosolized Florida red tide toxins: exposures and effects. Environ Health Perspect 113:618–620.

Fleming LE, Kirkpatrick B, Backer LC, Bean JA, Wanner A, Dalpra D, et al. 2005b. Initial evaluation of the effects of aerosolized Florida red tide toxins (brevetoxins) in persons with asthma. Environ Health Perspect 113:650–657.

Fleming LE, Kirkpatrick B, Backer LC, Bean JA, Wanner A, Reich A, et al. 2007. Aerosolized red tide toxins (brevetoxins) and asthma. Chest 131:187–194.

Kirkpatrick B, Bean JA, Fleming LE, Backer LC, Akers R, Wanner A, et al. 2009. Aerosolized red tide toxins (brevetoxins) and asthma: a 10 day follow up after 1 hour acute beach exposure. In: Proceedings of the 12th International Conference on Harmful Algae (Mooestrup Ø, Doucette G, Enevoldsen H, Godhe A, Hallegraff G, Luckas B, et al., eds). Copenhagen:International Society for Harmful Algae and Intergovernmental Oceanographic Commission of UNESCO, 297–299.

Kirkpatrick G, et al. 2008. Environmental exposures to Florida red tides: effects on emergency room respiratory diagnoses admissions. Harmful Algae 5:526–533

Kleinbaum DG, Kupper LL, Morgenstern H. 1982. Epidemiologic Research. New York:Van Nostrand Reinhold.

Martinez-Moragon E, Perpina M, Belloch A. 2006. Does experience influence perception of dyspnea? [in Spanish]. Arch Bronconeumol 42(4):171–174.

Milian A, Nierenberg K, Fleming LE, Bean JA, Wanner A, Reich A, et al. 2007. Reported respiratory symptom intensity in asthmatics during exposure to aerosolized Florida red tide toxins. J Asthma 44:583–587.

Naar J, Bourdelais A, Tomas C, Kubanek J, Whitney PL, Flewelling L, et al. 2002. A competitive ELISA to detect brevetoxins from Karenia brevis (formerly Gymnodinium breve) in seawater, shellfish, and mammalian body fluid. Environ Health Perspect 110:179–185.

NIOSH. 1997. NIOSH Spirometry Training Guide. Morgantown, WV:National Institute for Occupational Safety and Health.

Pierce RH, Henry MS, Blum PC, Lyons J, Cheng Y, Yazzie, et al. 2003. Brevetoxin concentrations in marine aerosol: human exposure levels during a K brevis harmful algal bloom. Bull Environ Contam Toxicol 70(1):161–185.

Tumpel DA, Fuhlbrigge AL. 2008. Defining the responder in asthma therapy. J Allergy Clin Immunol 121(3):466–469.

Van Dolah FM. 2000. Marine algal toxins: origins, health effects, and climate-related increased occurrence. Environ Health Perspect 108(suppl 1):133–141.

Watkins SM, Reich A, Fleming LE, Hammond R. 2008. Neurotoxic shellfish poisoning. Mar Drugs 6(3):431–455.

Zaizs J, Backer LC, Fleming LE. In press. Harmful algal blooms (HABs). In: Human-Animal Medicine: A Clinical Guide to Toxins, Zoonoses, and Other Shared Health Risks (Rabinowitz P, Conti L, eds). New York:Elsevier Science Publishers.